Lolitta Aznaurova, MD
Psychiatry · Leawood, KSNPI 1841270600
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 588 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in KS with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 588 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$1K
- Lundbeck LLC$780
- Johnson & Johnson$602
- Neurocrine Biosciences, Inc.$597
- Sunovion Pharmaceuticals Inc.$574
- plus $4K from 27 others
What the payments were for
- Food & beverage$10,571100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 105 | $2,399 |
| AbbVie(2 entities) | 99 | $1,486 |
| Lundbeck LLC | 50 | $780 |
| Johnson & Johnson | 36 | $602 |
| Neurocrine Biosciences, Inc. | 36 | $597 |
| Sunovion Pharmaceuticals Inc. | 47 | $574 |
| Teva Pharmaceuticals USA, Inc. | 21 | $568 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $420 |
| Corium, LLC | 11 | $403 |
| Vanda Pharmaceuticals Inc. | 14 | $392 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $388 |
| Axsome Therapeutics, Inc. | 13 | $286 |
| Avanir Pharmaceuticals, Inc. | 21 | $230 |
| Ironshore Pharmaceuticals Inc. | 9 | $171 |
| Neos Therapeutics, LP | 16 | $164 |
| Alkermes, Inc. | 8 | $159 |
| Supernus Pharmaceuticals, Inc. | 6 | $110 |
| Collegium Pharmaceutical, Inc. | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 5 | $94 |
| Almatica Pharma LLC | 6 | $93 |
| Bausch Health US, LLC | 4 | $85 |
| Tris Pharma Inc | 5 | $77 |
| Shire North American Group Inc | 6 | $77 |
| Jazz Pharmaceuticals Inc. | 4 | $73 |
| Arbor Pharmaceuticals, Inc. | 5 | $57 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Alfasigma USA, Inc. | 2 | $36 |
| Merck | 2 | $30 |
| Biogen | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Noven Therapeutics, LLC | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Harmony Biosciences LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$340
- REXULTI$247
- Azstarys$246
- ABILIFY ASIMTUFII$233
- ABILIFY MAINTENA$233
- Austedo XR$218
- NUEDEXTA$122
- AUSTEDO$111
- Fanapt$103
How this compares
$10,571 in reported general payments places this provider in the 90th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 12 | $94,227 |
| RexultiBrexpiprazole | 30 | $43,427 |
| VraylarCariprazine Hcl | 13 | $17,749 |
| TrintellixVortioxetine Hydrobromide | 21 | $14,923 |
| Aripiprazole | 120 | $4,746 |
| Duloxetine Hcl | 257 | $4,419 |
| Olanzapine | 109 | $3,659 |
| Clomipramine Hcl | 11 | $3,279 |
| Clonazepam | 272 | $2,427 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 161 | $2,132 |
| Lamotrigine | 220 | $2,121 |
| Bupropion XlBupropion Hcl | 91 | $2,003 |
| Alprazolam | 358 | $1,870 |
| Quetiapine Fumarate | 98 | $1,630 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 39 | $1,603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $597 | $94,22712 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,399 | $43,42730 claims |
| AbbVieVraylar | $1,486 | $17,74913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $420 | $14,92321 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $568 | $54712 claims |
| Almatica Pharma LLCSertraline Hcl | $93 | $504110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Leawood
- Kevin MaysLeawood$548K
- Sonni ElliottLeawood$22K
- Andrew SegravesLeawood$19K
- Michael EversonLeawood$19K
- Steven SegravesLeawood$13K
- Christopher van HornLeawood$10K
- Sherman ColeLeawood$8K
- Erick BrownLeawood$8K
- Wade HachinskyLeawood$7K
- Salma VelazquezLeawood$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.